Peroxisome Proliferator Activated Receptor-δ

Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study

“…Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that direct the transcription of genes involved in bile acids/sterols, lipids, and glucose metabolism, as well as inflammation. 12,13,14 Three PPAR subtypes, α, γ, and δ, are known 13 , each of which have their own distinct but overlapping cellular expression, target genes, pathway regulation, and biological functions. Fenofibrate, a PPAR-α agonist 15 , and bezafibrate, a pan-PPAR agonist 16 , have shown promising activity in decreasing markers of cholestasis in PBC subjects, although there are concerns about potential toxicity.…”